ロード中...
4CPS-157 Vedolizumab: early experience and medium-term outcomes in inflammatory bowel disease
BACKGROUND: Vedolizumab is a monoclonal antibody approved for the treatment of moderate to severe inflammatory bowel disease (IBD) for those patients who have had inadequate or loss of response or were intolerant to a tumour necrosis factor alpha inhibitor (anti-TNF-alpha). PURPOSE: To assess prescr...
保存先:
| 出版年: | Eur J Hosp Pharm |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535236/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.248 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|